David Shaw’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

David Shaw’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-121,286	Closed	-$3.26M	–	5991
2022 Q1	$3.26M	Buy	121,286 +17,130	+16%	+$576K	﹤0.01%	2796
2021 Q4	$4.97M	Sell	104,156 -5,262	-5%	-$235K	﹤0.01%	2389
2021 Q3	$7.27M	Sell	109,418 -19,601	-15%	-$1.4M	0.01%	1779
2021 Q2	$10.1M	Sell	129,019 -126,910	-50%	-$9.38M	0.01%	1488
2021 Q1	$24.2M	Buy	255,929 +161,628	+171%	+$19.2M	0.02%	834
2020 Q4	$11.5M	Buy	+94,301	New	+$10.3M	0.01%	1303
2020 Q3	–	Sell	-3,576	Closed	-$231K	–	4293
2020 Q2	$231K	Buy	+3,576	New	+$206K	﹤0.01%	3728
2020 Q1	–	Sell	-4,241	Closed	-$264K	–	4388
2019 Q4	$264K	Buy	+4,241	New	+$202K	﹤0.01%	3692

Other funds holding TPTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

David Shaw's TPTX Position: Q2 2022 in Review

David Shaw sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q2 2022, closing a stake of 121,286 shares — an estimated $3.26M sold.

David Shaw first reported a position in TPTX in Q4 2019 and held it in 8 quarters. The position peaked at $24.2M in Q1 2021. 208 funds tracked by Wall St. Rank hold TPTX as of Q2 2022.

David Shaw reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
David Shaw sold 121,286 Turning Point Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $3.26M.
David Shaw first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q4 2019 and held it in 8 quarters.
David Shaw's Turning Point Therapeutics, Inc. Common Stock position peaked at $24.2M in Q1 2021.
208 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q2 2022.

Based on D.E. Shaw & Co's 13F filing for Q2 2022, filed 15 Aug 2022.